Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | FABP4 | P15090 | 1/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530511 | 1.00 | MAPK1 (0.70) | MAPK1KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL11138401 | 0.94 | MAPK1 (0.63) | MAPK1KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL11137643 | 0.93 | MAPK1 (0.61) | MAPK1KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL27780501 | 0.92 | MAPK1 (0.61) | MAPK1KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL4313671 | 0.91 | HPGD (0.68) | MAPK1KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL97994 | 0.87 | LMNA (0.62) | MAPK1KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL30947438 | 0.85 | LMNA (0.78) | MAPK1LMNAALDH1A1HPGDMAPT | |
| SCHEMBL14664243 | 0.85 | LMNA (0.61) | MAPK1KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL133515 | 0.83 | LMNA (0.58) | MAPK1KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL13240512 | 0.83 | LMNA (0.58) | MAPK1KDM4EHSD17B10LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214551-B2 | One pot synthesis of 4-(1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)butanoic acid, a key intermediate of zilpaterol | RA CHEM PHARMA LIMITED (IN) | 2022-01-04 | — | — | US | claimed |
| US-20210238146-A1 | ONE POT SYNTHESIS OF 4-(1,2-DIHYDRO-2-OXOBENZO[D]IMIDAZOL-3-YL)BUTANOIC ACID, A KEY INTERMEDIATE OF ZILPATEROL | COHANCE LIFESCIENCES LIMITED (IN) | 2021-08-05 | — | — | US | claimed |
| CN-113200922-A | Process for preparing 2, 3-dihydro-2-oxo-1H-benzimidazole-1-butyric acid | 上海红象生物医药科技有限公司 | 2021-08-03 | — | — | CN | claimed |
| EP-2142553-B1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INT BV (NL) | 2015-08-19 | — | — | EP | claimed |
| US-8362006-B2 | Processes for making zilpaterol and salts thereof | INTERVET INTERNATIONAL B.V. (NL) | 2013-01-29 | — | — | US | claimed |
| EP-2535340-A2 | Process for making zilpaterol and salts thereof | Intervet International B.V. (NL) | 2012-12-19 | — | — | EP | claimed |
| US-20100121050-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2010-05-13 | — | — | US | claimed |
| CN-101652368-A | Process for making zilpaterol and salts thereof | INTERVET INT BV NL | 2010-02-17 | — | — | CN | claimed |
| EP-2142553-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | Intervet International B.V. (NL) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119754-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2008-10-09 | — | — | WO | claimed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2008044127-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044127-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| EP-0107569-B1 | 6-AMINO-7-HYDROXY-4,5,6,7-TETRAHYDROIMIDAZO(4,5,1-J,K)(1)BENZAZEPIN-2(1H)-ONE DERIVATIVES, THEIR SALTS, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1987-03-18 | — | — | EP | disclosed |
| US-4585770-A | HYPOTENSIVES, VASODILATORS | ROUSSEL UCLAF (FR) | 1986-04-29 | — | — | US | disclosed |
| EP-0107569-A1 | 6-Amino-7-hydroxy-4,5,6,7-tetrahydroimidazo(4,5,1-j,k)(1)benzazepin-2(1H)-one derivatives, their salts, their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | MAPK1 4362/4885KDM4E 2875/4885HSD17B10 2665/4885 |
| US-20210238146-A1 | ONE POT SYNTHESIS OF 4-(1,2-DIHYDRO-2-OXOBENZO[D]IMIDAZOL-3-YL)BUTANOIC ACID, A KEY INTERMEDIATE OF ZILPATEROL | CYP51A1, MED1, AZI2 | MAPK1 1826/4885KDM4E 820/4885HSD17B10 419/4885 |
| US-11214551-B2 | One pot synthesis of 4-(1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)butanoic acid, a key intermediate of zilpaterol | CYP51A1, MED1, AZI2 | MAPK1 1826/4885KDM4E 820/4885HSD17B10 419/4885 |
| US-20100121050-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | SLC39A11, SLC39A3, ZFR | MAPK1 2812/4885KDM4E 2828/4885HSD17B10 429/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | MAPK1 3671/4885KDM4E 791/4885HSD17B10 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.